REVIVOCELL INC

Capabilities

Revivocell Inc. develops next-generation human-relevant microphysiological systems (MPS) for drug discovery, safety, and efficacy testing. Using its patented NANOSTACKS™ and CELLBLOKS® platforms, Revivocell recreates complex multicellular human organ and multi-organ models that incorporate physiological flow, immune competence, and AI-driven analytics. These animal-free systems enable predictive modeling of disease and drug response in liver, brain, and barrier tissues, supporting FDA Modernization Act 2.0 and Next-Generation Risk Assessment (NGRA) initiatives. The company’s PhD-level team integrates tissue engineering, stem-cell biology, and data science to deliver validated, reproducible models that accelerate translational innovation for government, pharmaceutical, and academic partners.